The gross margin of Swedish biopharmaceutical company Sobi was down at the lowest point in 2011 at 51 percent, but then generally increased the following years. In 2024, the gross margin of Sobi stood at 78 percent. The company's full name is Swedish Orphan Biovitrum AB. Sobi is specialized on the treatment of rare diseases.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Sobi, & Nasdaq Nordic. (March 31, 2025). Gross margin of Sobi from 2009 to 2024 [Graph]. In Statista. Retrieved June 04, 2025, from https://www.statista.com/statistics/946949/gross-margin-of-sobi/
Sobi, und Nasdaq Nordic. "Gross margin of Sobi from 2009 to 2024." Chart. March 31, 2025. Statista. Accessed June 04, 2025. https://www.statista.com/statistics/946949/gross-margin-of-sobi/
Sobi, Nasdaq Nordic. (2025). Gross margin of Sobi from 2009 to 2024. Statista. Statista Inc.. Accessed: June 04, 2025. https://www.statista.com/statistics/946949/gross-margin-of-sobi/
Sobi, and Nasdaq Nordic. "Gross Margin of Sobi from 2009 to 2024." Statista, Statista Inc., 31 Mar 2025, https://www.statista.com/statistics/946949/gross-margin-of-sobi/
Sobi & Nasdaq Nordic, Gross margin of Sobi from 2009 to 2024 Statista, https://www.statista.com/statistics/946949/gross-margin-of-sobi/ (last visited June 04, 2025)
Gross margin of Sobi from 2009 to 2024 [Graph], Sobi, & Nasdaq Nordic, March 31, 2025. [Online]. Available: https://www.statista.com/statistics/946949/gross-margin-of-sobi/
